Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
Ocular Therapeutix Announces Its First Published Physician Fee Schedule for Administration of Intracanalicular Inserts
11:00am, Wednesday, 15'th Jul 2020
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today
Ocular Therapeutix Announces Its First Published Physician Fee Schedule for Administration of Intracanalicular Inserts
12:00am, Wednesday, 15'th Jul 2020
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera
Cloud Charts Tell Me To Wait Until I See Sunshine
07:56am, Tuesday, 14'th Jul 2020
My favorite screeners have been affected by the pandemic volatility, but less than I expected. The majority of stocks seem to range and wait for earnings data - not too much betting in either directio
Ocular Therapeutix Is A Good Value Based On Its Strong Technology Platform (NASDAQ:OCUL)
06:02am, Thursday, 09'th Jul 2020
Ocular Therapeutix already has one marketed product and several promising pipeline therapies using its novel implant technology for the treatment of eye diseases.
OCULAR THERAPEUTIX, INC : Submission of Matters to a Vote of Security Holders (form 8-K) | MarketScreener
08:17pm, Wednesday, 01'st Jul 2020Zymeworks (NYSE:ZYME) & Ocular Therapeutix (NYSE:OCUL) Critical Comparison
02:38am, Wednesday, 01'st Jul 2020
Zymeworks (NYSE:ZYME) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
12:00am, Friday, 26'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 25)
Brainstorm Cell...
The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs
12:00am, Friday, 19'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 18)
ADC Therapeutics SA (NYSE:...
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
12:00am, Thursday, 18'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
Adverum Biotechnologies Inc...
The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked
12:00am, Wednesday, 17'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hour.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 16)
ADC Therapeutics SA (NYSE:...
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
12:00am, Tuesday, 16'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 16)
Applied Molecular Transport...
Ocular Therapeutix™ to Hold Virtual 2020 Annual Meeting Of Stockholders
08:01pm, Monday, 15'th Jun 2020
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today
Ocular Therapeutix™ to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
12:00pm, Monday, 15'th Jun 2020
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, annou
Should You Avoid Ocular Therapeutix Inc (OCUL)?
12:24am, Monday, 15'th Jun 2020
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Ma
